GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation Covid-19 vaccine and therapy for advanced head and neck cancer. Additional development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg), malaria and Zika virus, as well as therapies for various solid tumors.

At GeoVax, we are guided by the following strategic imperatives as we develop and grow our Company:

• Innovate – Pursuing the development of unique, patented products addressing unmet medical needs

• Differentiate – Targeting populations underserved by existing products/standard of care

• Accelerate – Focused on expedited registration pathways

• Collaborate – Achieve worldwide distribution via business collaborations